Education
About Us
Working with TipRanks
Follow Us
Kate Haviland Insider Profile
4 Followers
Kate Haviland, CEO at Blueprint Medicines, holds 168.43K shares in Blueprint Medicines (Ticker: BPMC), holds ― shares in Fulcrum Therapeutics (Ticker: FULC), holds ― shares in Bicara Therapeutics Inc. (Ticker: BCAX). Most recently, Kate Haviland Sold ― shares of Blueprint Medicines on Mar 07, 2025 for an estimated value of 1.43M.
Profitable Transactions
4 out of 7 Profitable Transactions
Average Return
-20.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Kate Haviland holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Mar 05, 2021 - Mar 05, 2022
Return:+40.50%
The most profitable trade made by Kate Haviland
Kate Haviland's Trading History
Blueprint Medicines
Mar 07, 2025
CEO
Informative Sell
1.43M
$14.67M
Fulcrum Therapeutics
―
Director
―
―
Bicara Therapeutics Inc.
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Kate Haviland's performance on stock
You May Also Like
Kate Haviland insider profile FAQ
What is the percentage of profitable transactions made by Kate Haviland?
The percentage of profitable transactions made by Kate Haviland is 57%.
What is the average return per transaction made by Kate Haviland?
The average return per transaction made by Kate Haviland is -20.30%.
What stocks does Kate Haviland hold?
Kate Haviland holds: BPMC, FULC, BCAX stocks.
What was Kate Haviland’s latest transaction?
Kate Haviland latest transaction was an Informative Sell of $1.43M.
What was Kate Haviland's most profitable transaction?
Kate Haviland’s most profitable transaction was an Informative Sell of BPMC stock on March 5, 2021. The return on the trade was 40.50%.
What is Kate Haviland's role in Blueprint Medicines?
Kate Haviland's role in Blueprint Medicines is CEO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.